GRI Bio Inc.

GRI Bio, Inc. is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes therapies for inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead candidate, GRI-0621, is an oral inhibitor of type 1 Natural Killer T cells in a phase IIa trial for severe fibrotic lung diseases such as idiopathic pulmonary fibrosis. The portfolio also includes GRI-0803, a preclinical oral agonist of type 2 Natural Killer T cells for autoimmune disorders, a proprietary library of over 500 compounds, and GRI-0124 and GRI-0729 for balancing inflammatory immune responses. Formerly known as Glycoregimmune, Inc., the company was founded in 2009 and is based in La Jolla, California.

GRI▲

GRI Bio Upgraded to Zacks Rank #2 Buy on Rising Earnings Estimates

GRI Bio, Inc. has been upgraded to a Zacks Rank #2 (Buy), a rating that reflects an upward trend in earnings estimates. The company is expected to earn -$3.75 per share for the fiscal year ending December 2026, representing no year-over-year change, while over the past three months the Zacks Consensus Estimate for GRI Bio has increased 21.5%. The upgrade places GRI Bio in the top 20% of the more than 4,000 stocks covered by the Zacks Rank system, which assigns only the top 5% a Strong Buy rating and the next 15% a Buy rating. Zacks said the improved earnings outlook could translate into buying pressure and a higher stock price in the near term.

GRI ▲

Zacks Investment Research·4dRead more →